Swedish Orphan Biovitrum (SOBI.ST) Financial Analysis & Valuation | Quarter Chart
Swedish Orphan Biovitrum (SOBI.ST)
SOBI.STPrice: $47.55
Fair Value: 🔒
🔒score
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemoph... more
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manuf... more
Description
Shares
| Market Cap | $16.45B | Exchange | STO |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | SE | CEO | Guido Oelkers |
| IPO Date | 2006-09-15 | CAGR | 0.14% |
| Employees | 1,868 | Website | www.sobi.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SOBI.ST chart loading...
Fundamentals
Technicals
| Enterprise Value | $153.82B | P/E Ratio | 166.92 |
| Forward P/E | 20.44 | PEG Ratio | 3.57 |
| P/S Ratio | 5.29 | P/B Ratio | 3.8 |
| P/CF Ratio | 20.73 | P/FCF Ratio | 22.86 |
| EPS | $0.28 | EPS Growth 1Y | -77.76% |
| EPS Growth 3Y | -75.51% | EPS Growth 5Y | -72.69% |
| Revenue Growth 1Y | 10.36% | Gross Margin | 0.44% |
| Operating Margin | 0.3% | Profit Margin | 0.03% |
| ROE | 0.02% | ROA | 0.01% |
| ROCE | 0.14% | Current Ratio | 0.7 |
| Quick Ratio | 0.47 | Cash Ratio | 0.04 |
| Debt/Equity | 0.47 | Interest Coverage | 15.04 |
| Altman Z Score | 3 | Piotroski Score | 6 |